Abstract
Thus far, five molecules comprise the natriuretic peptide family (NPF): ANP, urodilatin, BNP, CNP and DNP. Precursor hormones for ANP, BNP and CNP are encoded by a different gene. Final peptides are ligands for A, B and C receptors, acting the latter as a clearance receptor besides neutral endopeptidase (EC 24.11). cGMP acts as a second messenger. Natriuretic peptides (NP) have well-known functions such as natriuretic, antihypertensive and reduction of plasma renin-aldosterone concentrations. An antiinflammatory ANP potential and a pro-apoptotic action in rats endothelial cells of different NP have been described. Unlike adults, NP show a different distribution during ontogeny and a different pattern of excretion under different stimuli. Noncompetitive immunoassays have become more suitable than competitive ones for routine measurement of NP with recent advances in speed of measurement. BNP and pro-BNP are emerging as useful tools in diagnosis, management and prognosis of heart disease. Preliminary data support a role of NP in the therapy of congestive heart failure. Finally, potential therapeutic compounds of NP in different pathologies are updated with an important focus on vasopeptidase inhibitors. These are capable of strengthening NP and inhibiting renin-angiotensin system at the same time, as potential useful molecules in cardiovascular therapy.
Keywords:natriuretic peptides,anp,urodilatin,bnp,pro-bnp,cnp,dnp,vasopeptidase inhibitors
Current Medicinal Chemistry - Cardiovascular & Hematological Agents
Title: Natriuretic Peptide Family: New Aspects
Volume: 3Issue: 2
Author(s):Luis Bolanos Cea
Affiliation:
Keywords:natriuretic peptides,anp,urodilatin,bnp,pro-bnp,cnp,dnp,vasopeptidase inhibitors
Abstract: Thus far, five molecules comprise the natriuretic peptide family (NPF): ANP, urodilatin, BNP, CNP and DNP. Precursor hormones for ANP, BNP and CNP are encoded by a different gene. Final peptides are ligands for A, B and C receptors, acting the latter as a clearance receptor besides neutral endopeptidase (EC 24.11). cGMP acts as a second messenger. Natriuretic peptides (NP) have well-known functions such as natriuretic, antihypertensive and reduction of plasma renin-aldosterone concentrations. An antiinflammatory ANP potential and a pro-apoptotic action in rats endothelial cells of different NP have been described. Unlike adults, NP show a different distribution during ontogeny and a different pattern of excretion under different stimuli. Noncompetitive immunoassays have become more suitable than competitive ones for routine measurement of NP with recent advances in speed of measurement. BNP and pro-BNP are emerging as useful tools in diagnosis, management and prognosis of heart disease. Preliminary data support a role of NP in the therapy of congestive heart failure. Finally, potential therapeutic compounds of NP in different pathologies are updated with an important focus on vasopeptidase inhibitors. These are capable of strengthening NP and inhibiting renin-angiotensin system at the same time, as potential useful molecules in cardiovascular therapy.
Export Options
About this article
Cite this article as:
Cea Bolanos Luis, Natriuretic Peptide Family: New Aspects, Current Medicinal Chemistry - Cardiovascular & Hematological Agents 2005; 3 (2) .https://dx.doi.org/10.2174/1568016053544309
DOI https://dx.doi.org/10.2174/1568016053544309 | Print ISSN 1568-0169 |
Publisher Name Bentham Science Publisher | Online ISSN 1875-6174 |
Related Articles
- A Review of Statistical and Machine Learning Techniques for Microvascular Complications in Type 2 Diabetes
Current Diabetes ReviewsUnmasking the Many Faces of Giloy (<i>Tinospora cordifolia</i> L.): A Fresh Look on its Phytochemical and Medicinal Properties
Current Pharmaceutical DesignAdvances in Anti-metabolic Disease Treatments Targeting CD47
Current Pharmaceutical Design Hepatoma Derived Growth Factor is a Nuclear Targeted Mitogen
Current Drug TargetsThe Association of Fractalkine Receptor (T280M) Polymorphism in the Pathogenesis of Acute Coronary Syndrome in the Egyptian Population
Current Pharmaceutical BiotechnologyMicroRNA-130a Regulation of Desmocollin 2 in a Novel Model of Arrhythmogenic Cardiomyopathy
MicroRNAAre the Myokines the Mediators of Physical Activity-Induced Health Benefits?
Current Pharmaceutical DesignC-reactive Protein, Infection, and Outcome After Acute Ischemic Stroke: A Registry and Systematic Review
Current Neurovascular ResearchUbiquitin and ubiquitin-like proteins in cardiac disease and protection
Current Drug Targets Targeting the Renin-angiotensin System: Whats New?
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Cardiovascular Disease: An Economical Perspective
Current Pharmaceutical Design Insulin Resistance as a Proinflammatory State: Mechanisms, Mediators, and Therapeutic Interventions
Current Drug TargetsNovel Neuroendocrine and Metabolic Mechanism Provides the Patented Platform for Important Rejuvenation Therapies: Targeted Therapy of Telomere Attrition and Lifestyle Changes of Telomerase Activity with the Timing of Neuron-Specific Imidazole-Containing Dipeptide-Dominant Pharmaconutrition Provision
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Stearoyl-CoA Desaturase-1 and the Metabolic Syndrome
Current Drug Targets - Immune, Endocrine & Metabolic DisordersProtein Kinases and Associated Pathways in Pluripotent State and Lineage Differentiation
Current Stem Cell Research & TherapyMicroRNA 21 Emerging Role in Diabetic Complications: A Critical Update
Current Diabetes Reviews Dietary Factors Influencing Magnesium Absorption in Humans
Current Nutrition & Food ScienceUse of Three-dimensional Printing in the Development of Optimal Cardiac CT Scanning Protocols
Current Medical ImagingGenistein in the Treatment of Hypertension: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Notch Signaling in Cardiovascular Disease and Calcification
Current Cardiology Reviews
[8]ページ先頭